7.3.1.1.2 Summary of evidence and recommendations for local therapy of advanced/metastatic RCC,
Recommendations  Strength rating,
Treatment-naïve patients,
Offer treatment with PD1 combinations in centres with experience.,Weak
"Offer either nivolumab plus ipilimumab, pembrolizumab plus axitinib, or lenvatinib   plus pembrolizumab, or nivolumab plus cabozantinib to treatment-naive patients   with IMDC intermediate- or poor-risk disease.",Strong
"Offer either pembrolizumab plus axitinib, lenvatinib plus pembrolizumab or   nivolumab plus cabozantinib to treatment-naïve patients with IMDC favourable risk.",Weak
Offer sunitinib or pazopanib to treatment-naive patients with IMDC favourable risk.,Weak
Offer sunitinib or pazopanib to treatment-naive cc-mRCC patients with any IMDC   risk who cannot receive or tolerate immune checkpoint inhibition.,Strong
"Patients who do not receive the full four doses of ipilimumab due to toxicity should   continue on single-agent nivolumab, where safe and feasible. Re-challenge with   combination therapy requires expert support.",Weak
Sequencing systemic therapy,
Sequence systemic therapy in treating mRCC.,Strong
Offer VEGF-tyrosine kinase inhibitors as second-line therapy to patients refractory   to nivolumab plus ipilimumab or axitinib plus pembrolizumab or cabozantinib plus   nivolumab or lenvatinib plus pembrolizumab.,Weak
Sequencing the agent not used as second-line therapy (nivolumab or cabozantinib)   for third-line therapy is recommended.,Weak
Offer nivolumab or cabozantinib to those patients who received first-line VEGF   targeted therapy alone.,Strong
